Last reviewed · How we verify
NCT05715710
Correlation Between Deep Medullary Veins and Cognitive Dysfunction in Cerebral Small Vessel Disease
trial in Cerebral Small Vessel Disease in 200 participants. Currently enrolling.
1 December 2025
Quick facts
| Lead sponsor | Zigong No.1 Peoples Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 1 January 2022 |
| Primary completion | 1 December 2025 |
| Estimated completion | 1 December 2025 |
| Sites | 1 location across China |
Conditions studied
- Cerebral Small Vessel Disease — all drugs for Cerebral Small Vessel Disease →
Sponsor
Zigong No.1 Peoples Hospital
Who can join
Adults 50 to 85, any sex, with Cerebral Small Vessel Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to obtain the characteristics of cognitive impairment and imaging characteristics of patients with Cerebral small vessel disease (CSVD) through comprehensive and standardized neuropsychological assessment and multimodal imaging examination. The focus is to obtain the characteristics of cognitive impairment and imaging characteristics of patients with CSVD through 3.0T MRI SWI sequence. deep medullary veins (DMVs) were measured. To compare the demographic data, hematological indexes, imaging scores and the number of DMVs between CSVD groups with and without cognitive impairment, and to explore the correlation between deep medullary veins and cognitive dysfunction in cerebral small vessel disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05715710
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cerebral Small Vessel Disease
Currently open trials in the same condition.
- NCT07068620 — Neurophysiological and Behavioral Study of the Cognitive Deficits Associated With Cerebral Small Vessel Disease in the S · NA · recruiting
- NCT06674460 — Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease · Phase 3 · recruiting
Other Zigong No.1 Peoples Hospital trials
Trials by the same sponsor.
- NCT03411967 — Apatinib in Combination With Docetaxel for Patients With Advanced NSCLC · Phase 2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05715710 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zigong No.1 Peoples Hospital
- Last refreshed: 28 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05715710.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing